Study: Genetic information can encourage women to accept preventive cancer treatment
CHICAGO ?-- Studies show that the risk of breast cancer can be reduced by half through the use of a five-year course of tamoxifen or raloxifene, and also by aromatase inhibitors. Nevertheless, women at high risk of breast cancer have a low acceptance of preventive medicine. A new study by Mayo Clinic and collaborators at [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - June 2, 2019 Category: Hospital Management Source Type: news

Riskreducing medications for primary breast cancer: a network metaanalysis
This Cochrane Review of 6 studies (n=50,927 on 1 cancer prevention agent (CPA:tamoxifen/raloxifene/exemestane/anastrozole] or placebo) found for women at above ‐average risk of developing breast cancer, CPAs can reduce incidence of this disease. Aromatase inhibitors appear to be more effective. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 29, 2019 Category: Consumer Health News Source Type: news

Role of Chemopreventive Agents in Women at Increased Risk for Breast Cancer
Cancer Network spoke with Charles Shapiro, MD, about the USPSTF ' s stance on use of tamoxifen, raloxifene, and aromatase inhibitors to prevent breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 18, 2019 Category: Cancer & Oncology Authors: Charles Shapiro, MD Source Type: news

USPSTF: Offer Breast Ca Meds to Women at Higher Risk
(MedPage Today) -- But task force says " no " to tamoxifen, raloxifene, or AIs for women at lower risk (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 16, 2019 Category: Hematology Source Type: news

Tamoxifen and raloxifene slow down the progression of muscular dystrophy
(Elsevier) Steroids are currently the only available treatment to reduce the repetitive cycles of inflammation and disease progression associated with functional deterioration in patients with muscular dystrophy (MD). A study reported in The American Journal of Pathology showed that a new treatment approach using the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene significantly improved cardiac, respiratory, and skeletal muscle functions and increased bone density in both male and female mice with the same gene defects as a subset of patients with MD. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 20, 2018 Category: Biology Source Type: news

Evista (Raloxifene) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 3, 2016 Category: Drugs & Pharmacology Source Type: news

Evista (raloxifene)
Title: Evista (raloxifene)Category: MedicationsCreated: 7/23/1998 12:00:00 AMLast Editorial Review: 9/30/2016 12:00:00 AM (Source: MedicineNet Menopause General)
Source: MedicineNet Menopause General - September 30, 2016 Category: Primary Care Source Type: news

Evista Blunts Symptoms in Women With Schizophrenia
(MedPage Today) -- No safety issues in small study, but thromboembolic risk remains concern (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - July 21, 2016 Category: Psychiatry Source Type: news

VIDEO: Advice varies for chemoprevention, genetic testing in invasive breast cancer
MIAMI – The message from major trials evaluating tamoxifen, raloxifene, and aromatase inhibitors for chemoprevention of invasive breast cancer got clearer with data from extended follow-up coming in.... (Source: Family Practice News)
Source: Family Practice News - March 12, 2016 Category: Primary Care Source Type: news

Raloxifene in Postmenopausal SchizophreniaRaloxifene in Postmenopausal Schizophrenia
Raloxifene improves negative symptoms in postmenopausal women with schizophrenia on antipsychotic treatment, a new study in 70 patients shows. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 16, 2015 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Raloxifene Fails to Affect Cognition in Alzheimer's Disease (CME/CE)
(MedPage Today) -- But subtle benefits can't be ruled out (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - November 5, 2015 Category: Geriatrics Source Type: news

No Cognitive Benefit of Raloxifene in Women with Alzheimer's No Cognitive Benefit of Raloxifene in Women with Alzheimer's
The selective estrogen receptor modulator failed to improve cognition in a small study of women with AD, although the possibility of a small cognitive benefit can't be excluded, researchers say. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 5, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Hormone-Like Drug Doesn't Help Women With Alzheimer's: Study
Researchers find no benefits from raloxifene in those with mild to moderate dementia (Source: WebMD Health)
Source: WebMD Health - November 4, 2015 Category: Consumer Health News Source Type: news

The Estrogen Drug That Reduces Your Breast...
Evista (raloxifene) is a drug that has been used for treatment of osteoporosis in postmenopausal women. The FDA has also approved it for prevention of invasive breast cancer. Evista creates an estrogen blockade, which lowers the incidence of estrogen-sensitive breast cancer. Learn more about Evista - uses, side effects, and benefits. (Source: Breast Cancer)
Source: Breast Cancer - October 18, 2015 Category: Cancer & Oncology Authors: at Tags: health Source Type: news

Comparison of the Effects of the Selective Estrogen Receptor Modulators Ospemifene, Raloxifene, and Tamoxifen on Breast Tissue in Ex Vivo Culture
Explant tissue culture provides a model for studying the direct effects of steroid hormones, their analogs, and novel hormonally active compounds on normal freshly isolated human breast tissues (HBTs). For this purpose, pre- and postmenopausal HBTs can be maintained in this culture system. The results demonstrate that the morphological integrity of HBT explants can be maintained in tissue culture up to 2 weeks and expression of differentiation markers, steroid hormone receptors, proliferation and apoptosis ratios can be evaluated as a response to hormonal stimulation. This chapter describes an ex vivo culture model that we...
Source: Springer protocols feed by Biochemistry - October 12, 2015 Category: Biochemistry Source Type: news